PMS20 Treatment of Patients with Moderate and Severe Psoriasis – Cost-of-Illness in the Czech Republic  by Petrikova, A. et al.
pared to adalimumab and infliximab when using actual drug utilization data from
US commercially-insured population.
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OBJECTIVES: Transfusion of allogeneic blood still is common in orthopedic surgery
albeit associated with higher morbidity and mortality. This analysis evaluates from
the perspective of a German hospital the potential cost savings of Epoetin alfa
compared to predonated autologous blood transfusions or to no-blood-conserva-
tion-strategy during elective hip and knee replacement surgery by reducing allo-
geneic blood transfusions and their associated infectious adverse events.
METHODS: Individual patients (n  10,000) were created based on data from con-
trolled trials, the German DRG institute (InEK) and various publications and entered
into a stochastic model (Monte-Carlo) one of three treatment arms: Epoetin alfa,
preoperative autologous donation and no-blood-conservation-strategy. The model
is focused on the costs and events of the procedure and follow-up. The model was
validated by an independent external consultant. Clinical and economical vari-
ables were obtained from clinical trial databases, the German DRG System, patient
records and medical publications- in particular cost per transfusion (allogeneic red
blood cells: € 320/unit and autologous red blood cells: € 280/unit), pneumonia treat-
ment (€ 5,000), and length of stay (€ 300/day). Probabilistic sensitivity analyses were
performed to determine which, if any, factors had an influence on the model’s
clinical and cost outcomes. RESULTS:At acquisition costs of € 375/40,000 IE Epoetin
alfa is cost saving compared to autologous blood donation, and at € 185/40,000 IE
compared to no-blood-conservation-strategy. The results were most sensitive to
the cost of Epoetin alfa, blood units and hospital days. CONCLUSIONS: Upcoming
shortages and increasing prices of red blood cells will make Epoetin alfa an attrac-
tive blood conservation strategy for anemic patients at reasonable costs, due the
reduction in allogeneic blood transfusions and their associated infectious adverse
events.
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OBJECTIVES: Biologics represent significant costs of rheumatic diseases treatment.
Our study has focused on productivity comparison of rheumatoid arthritis (RA)
patients treated with biologics and patients on DMARDs who are indicated to bio-
logic treatment however therapy is unavailable due to economic limitations.
METHODS: Work Productivity and Activity Impairment Questionnaire (WPAI:RA)
was administered to two groups of patients - patients treated with biologics (n76)
with low disease activity and patients just on DMARDs (n23) with high disease
activity (DAS28 score  5,1). All patients were in productive age. Patients’ demo-
graphics, clinical and PRO parameters (DAS28, HAQ, time from diagnosis) and
working statuses we collected by rheumatologist. Productivity costs were calcu-
lated by friction cost approach using friction period of 130 work-days and average
monthly gross income as denominator. RESULTS: Mean patients= age on biologics
and on DMARDs were 41.0 years (21-61) and 45.7 (22 – 61), respectively. Mean time
from diagnosis of biologics and DMARDs groups were 13.5 and 11.6 years, respec-
tively. Average HAQ and DAS28 were 0.77 and 2.64, respectively for patients on
biologics and 1.14, 5.62, respectively for patients on DMARDs. Patients on biologics
were slightly more work-disable (26.3%) compare to 25.0% DMARDs patients. Over-
all work-impairment (for patients that reported any work-impairment) for patients
on biologics and for patients on DMARDs was 28.1% and 49.6%, respectively. Pa-
tients on biologics reported less reduction of daily activities (39.8%) in compare to
patients on DMARDs (50.5%). Average annual productivity costs per one patient on
biologics and for DMARDs patient were € 1802 and € 2769, respectively.
CONCLUSIONS: Despite of the fact, patients on biologics had longer time from
diagnoses, they reported significantly lower work-impairment and reduction of
daily activities in compare to DMARDs patients, which reflected about 53.6% higher
productivity costs for patients on DMARDs. Biologic treatment preserves produc-
tivity and save productivity costs.
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OBJECTIVES: International pharmacoeconomic studies suggest Health Assess-
ment Questionnaire (HAQ) as an important predictor of evaluation both direct and
productivity costs. Costs are supposed to increase with increasing HAQ score.
Therefore, we calculated direct and productivity costs for five groups of patients
according to their HAQ (0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, 2.1) to confirm this assump-
tion also in the Czech Republic. METHODS: This calculation was based on a retro-
spective cross-sectional study. We included 126 patients with rheumatoid arthritis,
aged 18-84 years either at working status, part-time disabled or full-time disabled.
For estimation of direct medical costs, we used microcosting method retrospec-
tively reviewing individual patients’ medical records. For calculation of productiv-
ity costs we excluded patients older than 63 years of age (retirement pensioners).
We used friction costs approach (FCA) with defined friction period of 130 workdays,
based on patients’ absenteeism. Productivity of part-time-disabled and full-time
disabled patients were assumed to be deteriorated by 52% and 70%, respectively,
based on the Czech law on pension insurance. The height of average monthly
income in year 2010, €960.3 was used as denominator. Costs were expressed as
mean value per one patient with RA in each of the HAQ-group. RESULTS: Average
patients= age was 57.3 years; average time from diagnosis was 17.5 years with mean
HAQ score 1.4 and mean DAS28 3.62. Mean annual medical direct costs, for each
HAQ-group, were €4076.7, €5950.2, €4691.3, €6932.1, and €6727.1, respectively. Mean
annual indirect costs associated with productivity loss were €481.5, €1178.6,
€1267.7, €1585.6, and €2122.5, respectively. CONCLUSIONS: Direct and productivity
costs for patients with rheumatoid arthritis are closely related to the height of HAQ
score. Total (direct and productivity) annual mean costs were €7135.6. 31.0% of all
patients were treated with biological treatment which represented up to 79.4% of
the overall direct medical costs.
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OBJECTIVES: To determine the healthcare resource use (HRU) and costs attribut-
able to osteoporosis and osteoporosis-related fractures in post-menopausal
women in Greece METHODS: A multi-point data collection procedure, based on
strictly-structured interviews with 137 geographically distributed physicians, was
used to construct and populate the disease management model for women with
post-menopausal osteoporosis (PMO) aged 50years. The model was further vali-
dated by a group of 12 experts. Secondly, all HRU items in the model were costed in
order to provide per-patient costs of treatment. Cost variables included costs of
consultations, laboratory tests, osteoporotic medication, dietary supplements,
hospitalization due to fractures and rehabilitation, allcalculated from a third-party
payer perspective (Euros, 2011) for a 1year timeframe (retrospective).RESULTS:The
mean annual cost per PMO patient was €1,384.67 (95%CI: 423.27 – 7281.16). When
distinguishing between women with established (PMO with a previous fracture)
(27.6% of total) and non-established PMO, the mean annual cost per patient was
€2027.46 (95%CI: 508.09-7241.90) and €1139.63 (95%CI: 461.86 - 1324.44) respectively.
For PMO women with an established osteoporosis for1year the mean annual cost
was significantly higher compared to those with an established osteoporosis for 
1year €2714.98 (95%CI: 820.17 – 7284.42) versus €1805.54 (95%CI: 508.09 – 7241.77).
The mean annual cost per patient with a fracture was €4,334.27 (95%CI: 1,452.86 –
10,730.17) for a hip, €2,723.27 (95%CI: 1,470.39 – 7,839.55) for a vertebral and
€1,731.35 (95%CI: 1,131.17 - 1,942.48) for a Colles fracture respectively. The sensi-
tivity analysis (10% change of baseline values) showed that the factors with the
greatest impact on total cost were the probability of established osteoporosis, the
probability of a fracture in the previous 12 months, cost of parathormone treatment
and the cost of patient monitoring. CONCLUSIONS: Treatment of osteoporosis is
costly. Efforts to control the main osteoporosis cost drivers and hence its economic
impact on the health care budgets, are necessary.
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OBJECTIVES: Psoriasis (prevalence 2-3%) is not directly life-threatening disease.
However, patients suffering from psoriasis and psoriatic arthritis (PsA) are experi-
encing lower quality of life. Treatment of these diseases represents a significant
financial burden for the healthcare system. METHODS: Study was based on 12-
months retrospective electronic questionnaire reported by dermatologist. We used
societal perspective using friction cost approach method for productivity costs
calculation. Patients’ demographics, clinical data (PASI and BSA index), direct costs
(inpatient/outpatient care, local/systemic treatment etc.), productivity costs (inva-
lidity, sick leave) and on QoL (EQ-5D, DLQI) were collected. RESULTS: A total of 256
patients participated in the study, average patients= age was 46.79 years (9-75
years), average time from diagnosis was 25.52 years with average PASI 13,76, BSA
28,09%, DLQI 11,74 and EQ-5D 0,7633. Occurrence of PsA was 34.4%. Major direct
costs driver was phototherapy (47% of direct costs), systematic treatment (17%) and
inpatient care (15%). Within the productive-age patients (18-63 years), 8.6% of pa-
tients were fully disabled, 7.4% partially disabled, 73% patients were work-active,
and 11% were unemployed, retired or students. 17.2% of work-active patients re-
ported incapacity to work with average duration of 33 days in previous 6 months.
Mean indirect costs associated with productivity loss were €848.3 per work-active
patient per year €1343.0 per work-active patient with PsA. Mean annual costs per
patient with moderate to severe psoriasis and/or PsA were calculated to €3736.5
(direct costs 77%, €2888.2). Mean annual costs per patient with PsA were €4328.3
including €2985.3 for direct costs (69%). CONCLUSIONS: Direct costs remain major
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drivers of cost consumption in the treatment of patients with psoriasis and PsA in
the Czech Republic. Cohort in our study was not treated with biological treatment
which would certainly increase the costs therefore further study is required to
access the cost-effectiveness of such treatment in the Czech Republic.
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OBJECTIVES: To estimate and compare cost-of-illness (COI) and health-related
quality of life (HRQOL) of rheumatoid arthritis (RA) and ankylosing spondylitis (AS)
in South Korea.METHODS: Patients with RA (n196) and AS (n191) were surveyed
by face-to-face interviews at the Rheumatology Clinic of Seoul National University
Hospital. Direct costs [medical costs (treatment, drug, private physiotherapy, tra-
ditional Chinese medicine, other alternative medicine), non-medical costs (travel,
dietary supplements, auxiliary device, home assistance)], indirect costs (produc-
tivity loss due to job loss and sick leave) and deterioration in HRQOL of RA and AS
patients were measured. HRQOL was assessed using KEQ-5D. Factors associated
with COI and HRQOL were analyzed using multiple regression and multivariate
logistic regression. RESULTS: COI of AS patients was more than double compared
to that of RA patients (RA: 6,446,376 Korean Won, AS: 12,433,629 Korean Won) but
HRQOL of RA patients was lower than that of AS patients (RA: 0.49, AS: 0.62). As
functional severity worsened in both diseases, the total costs increased accordingly
(RA: functional class (FC) I: 4,230,204 Korean Won, FC II: 7,250,674 Korean Won, FC
III: 8,046,434 Korean Won, FC IV: 8,206,215 Korean Won, AS: FC I: 8,125,096 Korean
Won, FC II: 13,995,292 Korean Won, FC III, IV: 30,118,247 Korean Won) and the
HRQOL scores decreased (RA: FC I: 0.67, FC II: 0.50, FC III: 0.29, FC IV: 0.23, AS: FC I:
0.72, FC II: 0.61, FC III, IV: 0.24). Functional severity was the major determinant of
COI and HRQOL in RA and AS. CONCLUSIONS: Although the HRQOL of AS patients
was not as low as that of RA patients, the COI of AS patients was higher than that
of RA patients. Considering the relatively low HRQOL and relatively low medical
costs of RA patients, re-examination of reimbursement plan of Korean National
Health Insurance is needed to figure out this problem.
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OBJECTIVES: Since the 1993 estimate of the burden of osteoporosis in Canada, the
population has aged and new treatment options have been introduced. The study
purpose was to estimate the current burden of illness due to osteoporosis in Cana-
dians aged 50 and over. METHODS: Analyses were conducted using five national
administrative databases from the Canadian Institute for Health Information for
the fiscal-year ending March 31 2008 (FY 2007/08). Gaps in national data were
supplemented by provincial data extrapolated to national levels. Osteoporosis-
related fractures of the hip, humerus, vertebra, wrist, other sites and multiple sites
were identified using a combination of most responsible diagnosis and interven-
tion codes. Fractures associated with severe trauma codes were excluded from the
analysis. Costs, expressed in 2010 dollars, were calculated for osteoporosis-related
hospitalizations, emergency care, same day surgeries, rehabilitation, continuing
care, home care, long-term care, prescription drugs, physician visits and produc-
tivity losses. Sensitivity analyses were conducted to measure the impact on the
results of key assumptions. RESULTS:Osteoporosis-related fractures were respon-
sible for 57,413 acute care admissions and 832,594 hospitalized days in FY 2007/08.
Acute care costs were estimated at $1.2 billion. When outpatient care, prescription
drugs and indirect costs were added, the overall yearly cost of osteoporosis was
over $2.3 billion for the base case analysis and as much as $3.9 billion if a proportion
of Canadians were assumed to be living in long-term care facilities due to
osteoporosis. CONCLUSIONS: Osteoporosis is a chronic disease that results in a
substantial economic burden to the Canadian society.
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OBJECTIVES: To examine annual indirect cost in large-scale rheumatoid arthritis
(RA) patient cohort (IORRA) in Japan. METHODS: From patients’ perspective, we
calculated indirect costs of RA patients, participants of the 15-17th IORRA studies
in Oct. 2007- Oct. 2008. Productivity losses due to occasional absence from working
and those due to permanent retirement were separately estimated, by multiplying
average time with average wage, stratified by age & sex distribution of the cohort.
We also assessed correlations between these costs and RA disease activity, disabil-
ity level and QOL. RESULTS: Data from 5284 RA patients were extracted. A total of
34.8% of those were staying working in spite of RA. However, 9.9% reduced there
working time and 8.4% quitted their job due to RA. In average, RA patient missed
435.1 working hours per 1year. By multiplying average wage, JPY1,753, annual in-
direct costs per RA patient was estimated to JPY762,000. For whole RA patients in
Japan (n700,000), it would be JPY53.3billion per year. These costs increased pro-
gressively with worsening RA disease activity, disability level, or QOL. For example,
patients with lower EQ-5D score (less than 0.5) missed more working time than
those with higher one did (more than 0.8). Average missed time for working and
annual indirect cost among them were 1,087hours versus 275.8 hours and
JPY1,906,000 versus JPY484,000, respectively. With same cohort data, we had al-
ready proved that direct costs also had same trend. Total costs for RA patient were
JPY4,800,000 (JPY2.9mil. for direct cost and JPY1.9mil. for indirect cost) for patients
with lower EQ-5D score and JPY1,800,000 (JPY1.3mil. for direct cost and JPY0.5mil.
for indirect cost) for patients with higher one from societal perspective.
CONCLUSIONS: Heavy economic burden lies in RA patients and grows heavier as
the disease state is exacerbated using IORRA database. The increase indirect cost
may be suppressed by proactively controlling RA.
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OBJECTIVES:To determine direct and indirect cost due to rheumatoid arthritis (RA)
and ankylosing spondylitis (AS) in Turkey. METHODS: An expert panel composed
of 21 experts chosen from all national tertiary care rheumatology units (n53) was
convened to estimate the direct and indirect costs of care of patients with RA and
AS in Turkey, using “cost-of-illness” methodology. To measure indirect costs, the
number of days of sick leave, the extent of disability, and the levels of early retire-
ment and early death were also evaluated. Lost productivity costs were calculated
using the “human capital approach”, based on the minimum wage. RESULTS: The
total annual direct costs were 2.917,03 Euro per RA patient and 3.565,9 Euro for each
AS patient. The direct costs were thus substantial, but the indirect costs were much
higher because of extensive morbidity and mortality rates. The total annual indi-
rect costs were 7.058,99 Euro per RA patient and 6.989,81 for each AS patient. Thus,
the total cost for each RA patient was 9.976,01 Euro and that for an AS patient
10.555,72 Euro, in Turkey. CONCLUSIONS: From the perspective of those who pay
for health care, both RA and AS has become a burden in Turkey. The cost of lost
productivity is higher than the medical cost. Another important conclusion is that
indirect costs constitute 70% and 66% of total costs in patients with RA and AS,
respectively. The annual cost of RA for whole Turkish population is 2.130.424.680
Euro. This amount contributes to 0.37% of the GDP in Turkey. Whereas for AS, the
annual cost of disease in Turkey is 2.209.201.904 Euro and this corresponds to 0.38%
of the GDP. To conclude, RA and AS diseases have total burden of 4.339.626.584 Euro
that is 0.75% of the Turkish GDP.
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OBJECTIVES: Evaluate direct costs for the treatment of patient with active juvenile
rheumatoid arthritis (JRA) in the inefficiency of conventional therapy. METHODS:
Direct costs applied to patient, health care and society in process of medical care
provision were evaluated. In the study direct costs included cost of biologics for the
treatment of active JRA, therapy cost of the most common side effects caused by
biologics use, cost of inpatient care and cost of out-patient diagnostic and treat-
ment of JRA patients. RESULTS: Therapy cost with Etanercept and Abatacept was
evaluated on the first stage including spending on one patient treatment with
active JRA with body weight 15 till 65 kg. during one year after three months of
inefficient conventional therapy. Biologics doses and dosing regimen were defined
on the basis of application sheet. Calculated annual therapy cost for Etanercept
varied from 11,752 EUR to 23,503 EUR depending on body weight and for Abatacept
from 8,879 EUR to 26,638 EUR respectively. During cost analysis authors considered
only very often (1/10) and often (1/100,  1/10) occurred side effects. Thus, cost
of side effects treatment caused by Etanercept use resulted in 44 EUR and for
Abatacept – 69 EUR. Next stage of cost analysis was evaluation of therapy cost for
patients with JRA according standard of inpatient treatment è standard of out-
patient treatment. Cost of 30 days of inpatient care and 14 months of out-patient
care was considered during cost analysis for the treatment of patients with JRA.
Cost of inpatient and out-patient care for patient with JRA excluding biologics cost
amounted to 33585 EUR. CONCLUSIONS: Finally total direct costs for the treatment
of patient with JRA during one year with body weight from 15 till 65 kilogram varied
from 45,380 EUR to 57,132 EUR for Etanercept and from 42,534 EUR to 60,292 EUR for
Abatacept respectively.
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